Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use

Sule, Olajumoke; Brown, Nicholas M.; Willocks, Lorna; Day, Jane; Shankar, Sonal; Palmer, C.; Burrows, Nigel

doi:10.1016/j.ijantimicag.2007.02.015

Cited by 24 publications

(14 citation statements)

References 15 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In countries where fusidic acid is clinically used, this compound can be delivered as intravenous, oral and/or topical (skin and ophthalmic) preparations. Unfortunately, the use of fusidic acid as topical monotherapy for chronic skin conditions appears to have resulted in the emergence of resistance both among S. aureus and CoNS in several countries, making this agent less active both for topical and systemic therapy [5,[10][11][12][13][14]. Such topical use of a valuable systemically active agent is generally considered to be ill advised [6].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada

Pfaller¹,

Castanheira²,

Sader³

et al. 2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada

Pfaller¹,

Castanheira²,

Sader³

et al. 2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Some authors have called for its topical use to be restricted or even abolished. 8,9 Nevertheless, mupirocin can only be administered topically and its efficacy on S. aureus carriage eradication has disseminated its use for nasal decolonization. 10 High-level mupirocin resistance, defined by minimum inhibitory concentration (MIC) ≥256µg/mL, has been increasingly reported and has emerged as a significant problem.…”

Section: Introductionmentioning

confidence: 99%

Staphylococcus aureus resistance to topical antimicrobials in atopic dermatitis

Bessa

Quinto

Machado

et al. 2016

An. Bras. Dermatol.

View full text Add to dashboard Cite

BackgroundTopical antimicrobial drugs are indicated for limited superficial pyodermitis treatment, although they are largely used as self-prescribed medication for a variety of inflammatory dermatoses, including atopic dermatitis. Monitoring bacterial susceptibility to these drugs is difficult, given the paucity of laboratory standardization.ObjectiveTo evaluate the prevalence of Staphylococcus aureus topical antimicrobial drug resistance in atopic dermatitis patients.MethodsWe conducted a cross-sectional study of children and adults diagnosed with atopic dermatitis and S. aureus colonization. We used miscellaneous literature reported breakpoints to define S. aureus resistance to mupirocin, fusidic acid, gentamicin, neomycin and bacitracin.ResultsA total of 91 patients were included and 100 S. aureus isolates were analyzed. All strains were methicillin-susceptible S. aureus. We found a low prevalence of mupirocin and fusidic acid resistance (1.1% and 5.9%, respectively), but high levels of neomycin and bacitracin resistance (42.6% and 100%, respectively). Fusidic acid resistance was associated with more severe atopic dermatitis, demonstrated by higher EASI scores (median 17.8 vs 5.7, p=.009). Our results also corroborate the literature on the absence of cross-resistance between the aminoglycosides neomycin and gentamicin.ConclusionsOur data, in a southern Brazilian sample of AD patients, revealed a low prevalence of mupirocin and fusidic acid resistance of S. aureus atopic eczema colonizer strains. However, for neomycin and bacitracin, which are commonly used topical antimicrobial drugs in Brazil, high levels of resistance were identified. Further restrictions on the use of these antimicrobials seem necessary to keep resistance as low as possible.

show abstract

“…In einer englischen Studie an 62 Patienten (retrospektiv, Fragebögen) wurde ein statistisch signifikanter Zusammenhang zwischen der Resistenzquote von Staphylococcus aureus gegenüber Fusidinsäure und der Anwendung der Substanz beschrieben . Während kurze Anwendungszeiten von zwei Wochen oder weniger das Resistenzprofil nicht veränderten, waren häufige intermittierende Anwendungen von topischer Fusidinsäure besonders kritisch.…”

Section: Bewertungen Einzelner Therapieverfahren Zur Medikamentösen Tunclassified

Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis]

Werfel

Aberer

Ahrens

et al. 2015

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use

Cited by 24 publications

References 15 publications

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada

Staphylococcus aureus resistance to topical antimicrobials in atopic dermatitis

Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis]

Contact Info

Product

Resources

About